[go: up one dir, main page]

BRPI0418317A - vacina de aumento de crescimento à base de epitopo de neutralização - Google Patents

vacina de aumento de crescimento à base de epitopo de neutralização

Info

Publication number
BRPI0418317A
BRPI0418317A BRPI0418317-7A BRPI0418317A BRPI0418317A BR PI0418317 A BRPI0418317 A BR PI0418317A BR PI0418317 A BRPI0418317 A BR PI0418317A BR PI0418317 A BRPI0418317 A BR PI0418317A
Authority
BR
Brazil
Prior art keywords
novel
vaccine
gdf8
growth enhancement
based growth
Prior art date
Application number
BRPI0418317-7A
Other languages
English (en)
Inventor
David E Junker
Mark D Cochran
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34748944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0418317(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of BRPI0418317A publication Critical patent/BRPI0418317A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

VACINA DE AUMENTO DE CRESCIMENTO à BASE DE EPITOPO DE NEUTRALIZAçãO. A presente invenção refere-se a peptídeos antigênicos, novos, da proteínas GDF8. A invenção também refere-se a proteínas de fusão compreendendo os novos peptídeos, imunógenos e vacinas baseadas nos novos petídeos e/ou proteínas de fusão. anticorpos que especificamente se ligam aos novos petídeos de GDF8 e métodos de tratamento de animais a fim de modular a atividade de GDF8, empregando vacinas ou anticorpos de acordo com a invenção.
BRPI0418317-7A 2003-12-31 2004-12-21 vacina de aumento de crescimento à base de epitopo de neutralização BRPI0418317A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53371903P 2003-12-31 2003-12-31
PCT/US2004/043125 WO2005066204A2 (en) 2003-12-31 2004-12-21 Neutralizing epitope-based growth enhancing vaccine

Publications (1)

Publication Number Publication Date
BRPI0418317A true BRPI0418317A (pt) 2007-05-02

Family

ID=34748944

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418317-7A BRPI0418317A (pt) 2003-12-31 2004-12-21 vacina de aumento de crescimento à base de epitopo de neutralização

Country Status (21)

Country Link
US (3) US7371726B2 (pt)
EP (1) EP1699820A2 (pt)
JP (2) JP2007535912A (pt)
KR (1) KR20060120229A (pt)
CN (1) CN1902221A (pt)
AR (1) AR047345A1 (pt)
AU (1) AU2004312411B8 (pt)
BR (1) BRPI0418317A (pt)
CA (1) CA2551877A1 (pt)
EC (1) ECSP066683A (pt)
IL (1) IL176494A0 (pt)
MX (1) MXPA06007514A (pt)
NO (1) NO20063478L (pt)
NZ (1) NZ547593A (pt)
PE (1) PE20051050A1 (pt)
RU (1) RU2422460C2 (pt)
SG (1) SG153874A1 (pt)
TW (1) TWI357906B (pt)
UA (1) UA93855C2 (pt)
WO (1) WO2005066204A2 (pt)
ZA (1) ZA200605227B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604011A4 (en) 2003-01-21 2009-12-09 Ptc Therapeutics Inc METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE THE EXPRESSION OF DEPENDENT GENES FROM A NON-TRANSLATED REGION, AND METHODS OF USING SAME
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
RU2422460C2 (ru) * 2003-12-31 2011-06-27 Шеринг-Плоу Лтд. Выделенный пептид, обладающий специфической связывающей анти-gdf-8 антитело активностью, выделенная молекула нуклеиновой кислоты, вектор экспрессии, клетка-хозяин, способ получения пептида, вакцинная композиция и способ вызывания иммунного ответа анти-gdf-8, способ скрининга для отбора анти-gdf-8 антитела и способ понижающего регулирования активности gdf-8 у животного
CA2582940A1 (en) 2004-09-30 2006-04-06 Orico Limited Myostatin isoform
JP2008526201A (ja) * 2004-12-30 2008-07-24 シェーリング−プラウ・リミテッド 中和エピトープベースの成長増強ワクチン
AU2006302494B2 (en) * 2005-10-06 2011-01-06 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
WO2008016314A1 (en) 2006-08-03 2008-02-07 Orico Limited Myostatin antagonists
PT2066695E (pt) 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
TW201447062A (zh) 2008-04-11 2014-12-16 Chugai Pharmaceutical Co Ltd 重複結合複數個抗原的抗原結合分子
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) * 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
EP2780368B1 (en) 2011-11-14 2018-01-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
AU2015365168B2 (en) 2014-12-19 2021-08-05 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
CN112142844A (zh) 2015-02-05 2020-12-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6877357B2 (ja) 2015-04-15 2021-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
BR112018004981A2 (pt) * 2015-09-15 2018-10-09 Scholar Rock, Inc. anticorpos anti-pró-miostatina/miostatina latente e usos destes.
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
MX2018008369A (es) 2016-01-08 2019-05-15 Scholar Rock Inc Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
EP3785728A3 (en) 2016-06-13 2021-04-28 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CA3088855A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
AU2019226551B2 (en) 2018-03-01 2025-02-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
WO1993008290A1 (en) 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
AU746643B2 (en) 1997-02-05 2002-05-02 Metamorphix International, Inc. Immunization against endogenous molecules
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
DE69941116D1 (de) 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
US6284882B1 (en) 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
CN1384757A (zh) * 1999-07-20 2002-12-11 法麦克萨有限公司 下调gdf－8活性的方法
AU4889100A (en) 1999-07-30 2001-02-01 Pfizer Products Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
WO2001026672A1 (en) 1999-10-13 2001-04-19 Roswell Park Memorial Institute Induction of a strong immune response to a self-tumor associated antigen
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP1572740A2 (en) 2002-12-11 2005-09-14 Pharmexa A/S Targeting single epitopes
WO2004058988A2 (en) 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
RU2422460C2 (ru) * 2003-12-31 2011-06-27 Шеринг-Плоу Лтд. Выделенный пептид, обладающий специфической связывающей анти-gdf-8 антитело активностью, выделенная молекула нуклеиновой кислоты, вектор экспрессии, клетка-хозяин, способ получения пептида, вакцинная композиция и способ вызывания иммунного ответа анти-gdf-8, способ скрининга для отбора анти-gdf-8 антитела и способ понижающего регулирования активности gdf-8 у животного
US20060281075A1 (en) * 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
JP2008526201A (ja) 2004-12-30 2008-07-24 シェーリング−プラウ・リミテッド 中和エピトープベースの成長増強ワクチン

Also Published As

Publication number Publication date
US7585648B2 (en) 2009-09-08
TW200526683A (en) 2005-08-16
EP1699820A2 (en) 2006-09-13
AU2004312411A1 (en) 2005-07-21
SG153874A1 (en) 2009-07-29
UA93855C2 (ru) 2011-03-25
US7892561B2 (en) 2011-02-22
AU2004312411B8 (en) 2011-11-24
ECSP066683A (es) 2006-10-25
JP2011083290A (ja) 2011-04-28
ZA200605227B (en) 2007-03-28
RU2006127314A (ru) 2008-02-10
CA2551877A1 (en) 2005-07-21
US20050143306A1 (en) 2005-06-30
NO20063478L (no) 2006-08-28
MXPA06007514A (es) 2006-08-31
AU2004312411B2 (en) 2011-11-03
CN1902221A (zh) 2007-01-24
AR047345A1 (es) 2006-01-18
TWI357906B (en) 2012-02-11
PE20051050A1 (es) 2005-12-12
WO2005066204A3 (en) 2005-08-11
US7371726B2 (en) 2008-05-13
US20080227156A1 (en) 2008-09-18
RU2422460C2 (ru) 2011-06-27
WO2005066204A2 (en) 2005-07-21
NZ547593A (en) 2009-09-25
JP2007535912A (ja) 2007-12-13
IL176494A0 (en) 2006-10-05
KR20060120229A (ko) 2006-11-24
US20090311282A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
MXPA05009580A (es) Vacuna contra el virus de la influenza.
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1122117T1 (el) Ενεργοποιηση μιας ανοσοαποκρισης
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
ATE406912T1 (de) Immunisierung gegen chlamydia tracheomatis
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
ATE542829T1 (de) Impfstoff
NZ627888A (en) Materials and methods for respiratory disease control in canines
CY1110634T1 (el) Μεθοδοι προληψης και θεραπειας της νοσου του αλτσχαϊμερ (ad)
BR0113112A (pt) Anticorpos, de integrina antidual, composições, métodos e usos
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
ATE440861T1 (de) Immunisierung gegen chlamydia pneumoniae
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
ATE219687T1 (de) Verwendung von antikörpern zur vakzinierung gegen krebs
PT1112747E (pt) Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
ATE345354T1 (de) Methode zur identifizierung von helicobacter antigenen
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
CL2010001175A1 (es) Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
WO2006071896A3 (en) Epitope-based sars vaccine
EP0652769A1 (en) Vaccines against Metazoon parasites.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.